Phase II tumor volume-influenced dose escalation of accelerated hyperfractionated RT to 64.0 & 70.4 GY with BCNU for newly diagnosed radiosurgery-ineligible glioblastoma multiforme (GBM) patients (RTOG 9411)

被引：1
|
作者：
Coughlin, C
Scott, C
Langer, C
Coia, L
Curran, W
Rubin, P
机构：
[1] DARTMOUTH HITCHCOCK MED CTR,LEBANON,NH 03766
[2] RTOG HEADQUARTERS,STAT UNIT,PHILADELPHIA,PA
[3] FOX CHASE CANC CTR,PHILADELPHIA,PA 19111
[4] COMMUNITY MED CTR,TOMS RIVER,NJ
[5] THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107
[6] UNIV ROCHESTER,ROCHESTER,NY
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1997年 / 39卷 / 02期
关键词：
D O I：
10.1016/S0360-3016(97)80829-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：270 / 270
页数：1
相关论文
共 4 条
  • [1] Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 gy) based on tumor volume (> 20 or ≤ 20 CM2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients
    Coughlin, C
    Scott, C
    Langer, C
    Coia, L
    Curran, W
    Rubin, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (05): : 1351 - 1358
  • [2] PHASE I/II TRIAL OF TEMOZOLOMIDE (TMZ), MOTEXAFIN GADOLINIUM (MGD), AND 60-GY FRACTIONATED RADIATION (RT) FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA: RESULTS OF RTOG 0513 PHASE I DOSE ESCALATION TOXICITY ANALYSIS
    Brachman, David
    Wang, Meihua
    Ashby, Lynn
    Stea, Baldassarre
    Thomas, Theresa
    Mehta, Minesh
    NEURO-ONCOLOGY, 2008, 10 (05) : 889 - 889
  • [3] A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)
    Sul, J.
    Panageas, K. S.
    Lassman, A. B.
    Hormigo, A.
    Nolan, C.
    Gavrilovic, I. T.
    Grimm, S. A.
    DeAngelis, L. M.
    Abrey, L. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)
    Clarke, Jennifer
    Sul, Joohee
    DeAngelis, Lisa
    Lassman, Andrew
    Hormigo, Adilia
    Nolan, Craig
    Gavrilovic, Igor
    Gu, Bin
    Panageas, Kathy
    Abrey, Lauren
    NEURO-ONCOLOGY, 2007, 9 (04) : 530 - 530
1